Replies to post #238547 on Innovation Pharmaceuticals Inc (IPIX)

[jav0033]

Our management and company is a joke. Can’t deliver and keep sliding Milestones.

No partneship by end of September wil be our final blow.

Thanks leo,

Sigh...

[kfcyahoo]

Epiricist1,

Thanks for the reply. I had not read it (your link did not include the report), so I googled the title included in your post and found it. Its in the link refernced below in case others were also unable to open the link.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918142/

kfc

[MinnieM]

I find mention of Brilacidin for Oral Mucositis (OM) in multiple studies. The ph2 was still ongoing for most, if not, all of them at the time the articles were being worked on.

Here's one:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439125/

Antimicrobial agents showed beneficial effect in prophylaxis and reduction of the severity of RIOM. RT injury leads to a change in the mucosal membrane barrier, salivary flow, and composition which favor the growth and colonization of different bacterial species, mainly Gram-negative bacteria. Many preclinical studies have investigated the therapeutic effect of different antimicrobial agents in RIOM (217–220). The FDA has granted fast track designation for brilacidin-OM, an oral rinse formulation of defensin-mimetic brilacidin (221–223), for the prevention of OM. There is a current phase II clinical trial to evaluate the safety and efficacy of brilacidin oral rinse in patients with head and neck cancer (NCT02324335).

In Reply to 'Empiricst1'
KFC, what bothers me is that the IPIX OM product is not among those studied, or even mentioned. The article was published June of this year. I presume most here read it.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
Author links open overlay panel Bryan Oronsky *, Sharad Goyal †, Michelle M. Kim ‡, Pedro Cabrales §, Michelle Lybeck *, Scott Caroen *, Neil Oronsky ¶, Erica Burbano *, Corey Carter #, Arnold Oronsky **
Show more
https://doi.org/10.1016/j.tranon.2018.03.014Get rights and content
Under a Creative Commons license

[loanranger]

The link is fixed easily by copying and pasting it without the "Get" at the end.

The IPIX Scientific Advisor on oral mucositis, Dr. Stephen Sonis, appears over a dozen times in the reference material. Given that, B's absence is even more surprising.

http://www.ipharminc.com/scientific-advisors/

[PlentyParanoid]

Maybe the emphasis on radioprotection has something to do with the scope of the article.

Amifostine and RRx-001 both originate from military radioprotective research. GC4419, a superoxide dismutase, has direct radioprotective properties by snubbing (not a scientific term, yet. I am working on it) superoxide radicals produced by radiation. Palifermin is not an actual radioprotective, but it is the only FDA approved drug for oral mucositis and probably serves as reference for the others. Excluded drugs, Dusquetide, Brilacidin, Validive, Epicatechin (EC-18) and AGO13 are more active in damage repair than in direct radioprotection.